Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2020)

Historic Change in Accured Expenses for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to -$21418.0.

  • Monopar Therapeutics' Change in Accured Expenses rose 8345.03% to -$21418.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $114857.0, marking a year-over-year increase of 32598.0%. This contributed to the annual value of $506791.0 for FY2024, which is 13800.35% up from last year.
  • As of Q3 2020, Monopar Therapeutics' Change in Accured Expenses stood at -$21418.0, which was up 8345.03% from $163152.0 recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Change in Accured Expenses ranged from a high of $304229.0 in Q4 2019 and a low of -$331106.0 during Q1 2020
  • Moreover, its 4-year median value for Change in Accured Expenses was $32544.0 (2018), whereas its average is $25946.9.
  • The largest annual percentage gain for Monopar Therapeutics' Change in Accured Expenses in the last 5 years was 88914.9% (2019), contrasted with its biggest fall of 105056.9% (2019).
  • Over the past 4 years, Monopar Therapeutics' Change in Accured Expenses (Quarter) stood at -$26070.0 in 2017, then skyrocketed by 436.24% to $87658.0 in 2018, then soared by 247.06% to $304229.0 in 2019, then tumbled by 107.04% to -$21418.0 in 2020.
  • Its Change in Accured Expenses stands at -$21418.0 for Q3 2020, versus $163152.0 for Q2 2020 and -$331106.0 for Q1 2020.